Business Highlights

Second-Quarter 2023 Results

Total Company

$10.0B 11.5%\(^1\)

Sales Worldwide

$1.08\(^2\)

Adjusted Diluted EPS

Continue to forecast

$4.30 to $4.50\(^3\)

Full-Year 2023 Adjusted Diluted EPS

Reflects increased outlook for underlying base business offset by lower forecasted earnings contribution from COVID-19 testing-related sales

Business Unit Sales

- $4.3B Medical Devices
- $2.3B Diagnostics
- $1.3B Established Pharmaceuticals
- $2.1B Nutrition

Business Highlights

Breaking New Ground in Leadless Pacemakers

- FDA approval of AVEIR® DR Dual Chamber Leadless Pacemaker System, the world’s first dual chamber leadless pacing system for people with abnormal or slow heart rhythms.
- Dual chamber, leadless synchronous or coordinated pacing is made possible with novel implant-to-implant (i2i\(^{TM}\)) communication technology.

Expanding Access to Life-Changing Technologies

- In France, the FreeStyle Libre\(^{TM}\) 2 system is now the first and only continuous glucose monitoring (CGM) system to receive expanded national reimbursement to include all people with diabetes who use insulin.
- In the U.S., the FreeStyle Libre\(^{TM}\) portfolio recently obtained significantly expanded coverage for Medicare beneficiaries.

Innovating to Treat Abnormal Heart Rhythm

- FDA approval of TactiFlex® Ablation Catheter, Sensor Enabled\(^{TM}\), the world’s first ablation catheter with a unique flexible electrode tip and contact force sensing to treat patients with atrial fibrillation.
- When used with the EnSite™ X EP System, physicians have better visualization, allowing for more accuracy and precision with the TactiFlex Ablation Catheter.

Advanced Diagnostics

- 11.5% organic sales growth for underlying base business\(^*\)**

- Reflects increased outlook for underlying base business offset by lower forecasted earnings contribution from COVID-19 testing-related sales

- In the U.S., the FreeStyle Libre® portfolio recently obtained significantly expanded coverage for Medicare beneficiaries.

Innovating to Treat Abnormal Heart Rhythm

- FDA approval of AVEIR® DR Dual Chamber Leadless Pacemaker System, the world’s first dual chamber leadless pacing system for people with abnormal or slow heart rhythms.
- Dual chamber, leadless synchronous or coordinated pacing is made possible with novel implant-to-implant (i2i\(^{TM}\)) communication technology.

- In France, the FreeStyle Libre\(^{TM}\) 2 system is now the first and only continuous glucose monitoring (CGM) system to receive expanded national reimbursement to include all people with diabetes who use insulin.
- In the U.S., the FreeStyle Libre\(^{TM}\) portfolio recently obtained significantly expanded coverage for Medicare beneficiaries.


**Excludes the impact of COVID-19 testing.

***Find important safety information about the FreeStyle Libre portfolio: www.freestylelibre.us/safety-information.

1. On a GAAP basis, second-quarter 2023 Abbott sales decreased 11.4%.

2. Second-quarter GAAP diluted EPS was $0.78.

3. Abbott projects full-year 2023 diluted earnings per share from continuing operations under GAAP of $3.02 to $3.22. Abbott forecasts specified items for the full-year 2023 of $1.28 per share primarily related to intangible amortization, restructuring and cost reduction initiatives and other net expenses. Excluding specified items, projected adjusted diluted earnings per share from continuing operations would be $4.30 to $4.50 for the full-year 2023. In the U.S., the FreeStyle Libre® portfolio recently obtained significantly expanded coverage for Medicare beneficiaries.

Forward-Looking Statements

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott’s operations are discussed in Item 1A, “Risk Factors” in our Annual Report on Form 10-K for the year ended Dec. 31, 2022, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.